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ABSTRACT 
Objective: To develop a reverse-phase high performance liquid chromatographic method for simultaneous estimation of methotrexate (MTX), 
dexamethasone (DXM) and indomethacin (IND). 
Methods: A simple, isocratic reverse-phase high performance liquid chromatographic (RP-HPLC) method has been developed for simultaneous 
estimation of methotrexate, dexamethasone and indomethacin using ibuprofen (IBP) as internal standard with photodiode array detection at 254 
nm. The process was carried out on C18 column (5 μm, 250 mm X 4.6 mm) using methanol: orthophosphoric acid (1.67 % v/v) in 70: 30 ratio at a 
flow rate of 1.5 ml per minute.  
Results: The retention time for MTX, DXM, IND and IBP were found to be 1.47, 4.05, 11.29 and 12.69 minutes, respectively. Calibration curves of the 
drugs were linear in the concentration range 1-500 μg/ml. The limit of detection and limit of quantitation was 3.3 ng and 10.9 ng for MTX, 0.3 and 
0.9 ng for DXM and 2.1 and 6.7 ng for IND respectively. The intra-day precision varied from 0.2 to 1.6 % and inter-day precision ranged from 0.2 to 
1.8 %. The intra-day accuracy ranged from 98.3 to 101.13 % while inter-day accuracy varied from 98.6 to 101.4 %.  
Conclusion: The developed method is ideally suited for simultaneous estimation of the drugs.  
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INTRODUCTION 
Rheumatoid arthritis is a chronic, systemic, inflammatory disorder 
of unknown etiology that primarily involves the joints but can also 
cause multiple extra-articular manifestations. Therapy has been 
targeted towards the treatment of the signs and symptoms of the 
disease as well as towards changing its natural history. Without 
disease modifying therapy patients with this disease neither enjoy 
an adequate health-related quality of life nor a normal life span. The 
drugs used either singly or in combination with each other include: 
Non-steroidal anti inflammatory drugs (NSAIDs), disease modifying 
anti-rheumatic drugs (DMARDs) and biologics/anticytokines. 
Combinations of agents from different classes are frequently 
employed in treatment [1]. 
Indomethacin, chemically 1-(4-chlorbenzoyl)-5-methoxy-2-
methylindoleacetic acid, is a NSAID analgetic and antipyretic drug. 
Its effect is based on inhibition of cyclo-oxygenase (COX). It is 
frequently used for the treatment of symptoms of rheumatoid 
arthritis. In veterinary medicine, it is effective in treatment of 
inflammatory processes related to infectious diseases. The drug is 
usually administered orally but can also be administered 
intravenously or as a suppository and topical gel [2, 3]. 
Dexamethasone chemically is 9-fluoro-11β, 17, 21-trihydroxy-16α-
methylpregna-1, 4-diene, 3, 20-dione. It is a synthetic adrenocortical 
steroid used to treat many different conditions such as allergic 
disorders, skin conditions, ulcerative colitis, arthritis, lupus, 
psoriasis, or breathing disorders [2, 3]. 
Chemically methotrexate is N- [4 (2, 4-diamino-6-pteridinyl) 
methyl] methyl-amino]benzoyl]-L-glutamic acid. It is used to treat 
rheumatoid arthritis as well as other rheumatic conditions such as 
juvenile arthritis, lupus, (also known as SLE), psoriatic arthritis and 
olymyositis (muscle inflammation) [2, 3]. 
Although there are number of HPLC methods for the determination 
of indomethacin [4-10], dexamethasone [10-16] and methotrexate 
[17-21] separately but to the best of our knowledge there is no HPLC 
method capable of determining simultaneously methotrexate, 
indomethacin and dexamethasone. Therefore, it was proposed to 
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Fig. 1: Chemical structures of drugs used in the study 
 
MATERIALS AND METHODS 
Methotrexate (Dabur, Ghaziabad, India), Indomethacin (Signa 
Pharma, Kanpur, India), Dexamethasone and Ibuprofen (Solicito 
Pharma, Sagar, India) were obtained as generous gift samples. 
Orthophosphoric acid was purchased from Merck (Mumbai, India), 
methanol and water of HPLC grade were purchased from 
Spectrochem (Mumbai, India), membrane filters 0.45 μm (Millipore, 
Bangalore, India) were used for the study.  
HPLC system 
The HPLC system used consisted of pump SHIMADZU, LC 2O AT 
prominence liquid chromatography with universal loop injector 
Rheodyne 7725 i of injection capacity 20 uL coupled with a 
prominence photodiode array detector SPD M20A (Shimadzu 
Corporation Kyoto, Japan). The column used was Luna C18 (2) 100 R 
(5 μm, 250 mm X 4.6 mm) (Phenomenex, UK). 
Chromatographic conditions 
The mobile phase used consisted of methanol: orthophosphoric acid 
(1.67% v/v in water) in the ratio 70:30. The mobile phase was 
filtered through 0.45 µm filter in a vacuum filtration assembly 
before use. The eluent was monitored with a UV-visible detector set 
at 254 nm with the pump flow rate set at 1.5 ml/min.  
Preparation of stock and working standard solutions 
Stock solutions of MTX, DXM, IND (1000 µg/ml of each) and the 
internal standard IBP (100 µg/ml) were prepared in mobile phase. 
The solutions were stored at 4°C and showed no significant 
alterations in peak areas determined daily by direct injection 
throughout the study. Working standard solutions were prepared 
from stock solutions with an appropriate amount of drugs and 
internal standard stock solution to obtain the final concentration 
ranging from 1-500 μg/ml of methotrexate, dexamethasone, 
indomethacin each, and 50 μg/ml of internal standard IBP.  
Assay validation [22-24] 
Intra-day (within a day) and inter-day (on consecutive days) 
precision and accuracy of the assay was determined as precision (CV 
%) and accuracy (%). The samples were prepared containing 10, 25, 
50, 100 μg/ml of drugs and analyzed. Three replicates of each 
concentration were analyzed on different days to determine inter-
day precision and accuracy. Recovery studies were performed by 
standard addition method. To an aliquot of the analyzed sample (50 
μg/ml) a known concentration of standard solutions was added (10, 
25, 50 μg/ml). The contents of MTX, DXM and IND were determined. 
The linearity of the method was studied by analyzing the drugs at 
different concentrations (range 1-500 μg/ml) for MTX, DXM and IND 
with 50 µg/ml internal standard. Calibration data were acquired by 
plotting the ratio of peak area of individual drugs to that peak area 
of internal standard against the concentration of the calibration 
standard followed by a regression analysis. The constructed plots 
were linear and the average corresponding regression equations 
were y = 0.0066x+0.0252 with correlation coefficient (r2) = 0.9995 
for DXM, y = 0.0042x+0.0147 and r2 = 0.9991 for MTX, and y = 
0.0025x+0.0078 and r2 = 0.9997 for IND, respectively where y is the 
ratio of peak area of drug to that of I. S. and x is the drug 
concentration (μg/ml). Specificity was carried out by injecting 
placebo solution. Limit of detection (LOD) and limit of quantitation 
(LOQ) were calculated using signal-to-noise (S/N) ratio method. 
LOD was taken as the concentration of analyte where S/N ratio was 
3 and LOQ was taken as the concentration of analyte where S/N 
ratio was 10. The chromatographic parameters were also validated 
by system suitability studies, which were carried out on freshly 
prepared stock solutions. Ruggedness of the proposed method was 
determined by analysis of aliquots from homogeneous slot in 
different laboratories of the department, by different co-analyst, 
using similar operational and environmental conditions. The % CV 
was found to be less than 2 %. 
RESULTS AND DISCUSSION 
The typical chromatogram obtained from the analyses of three 
drugs with internal standard is presented in fig. 2. In the present 
analytical conditions, the retention time obtained for the drugs 
was 1.47 minutes for MTX, 4.05 minutes for DXM, 11.29 minutes 
for IND and 12.69 minutes for IBP. The calibration curve was 
linear in the range 1-500 µg/ml for MTX (fig. 3), DXM (fig. 4) and 
IND (fig. 5). The limit of detection (LOD) and limit of quantification 
(LOQ) for MTX, DXM and IND are reported in table 3. Intra-day and 
inter-day precision and accuracy of the assay is ascertained as 
precision (%) and accuracy (%), respectively on the basis of 
published guidelines [23, 24]. The obtained results are shown in 
table 1. The % recovery of MTX was from 99.23 to 100.69 %, for 
DXM was 99.2 to 100.89 % and for IND it was from 99.42 to 100.7 
%. Results are shown in table 2. The results of ruggedness studies 
which were carried out using two similar HPLC in different 
laboratories by different analyst showed % CV<2 (table 4).  
 
 
Fig. 2: Typical chromatogram obtained 
 
Peak at 1.467 min-methotrexate, 3.335 min-dexamethasone, 10.784 
min-indomethacin and at 12.439 min-ibuprofen 
 
























Fig. 3: Linearly regressed calibration curve of methotrexate 
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Fig. 4: Linearly regressed calibration curve of dexamethasone 



























Fig. 5: Linearly regressed calibration curve of indomethacin
 
Table 1: Intra-day and Inter-day accuracy and precision of the assay 











MTX 10 10.11±.16 101.13 1.6 9.96±0.15 99.6 1.5 
25 25.13±0.25 100.52 1.0 25.35±0.45 101.4 1.8 
50 50.21±.12 100.42 0.2 50.57±.79 101.14 1.6 
100 98.36±1.29 98.36 0.3 99.99±.21 99.9 0.2 
DXM 10 9.97±0.09 99.7 0.9 9.96±0.14 99.6 1.4 
25 24.94±0.14 99.76 0.5 25.13±0.31 100.52 1.2 
50 49.97±.18 99.94 0.4 49.99±.19 99.98 0.4 
100 100.1±.15 100.1 0.2 100.06±.89 100.06 0.9 
IND 10 9.86±0.07 98.6 0.7 9.86±0.07 98.6 0.7 
25 25.17±0.35 100.68 1.4 25.1±0.1 100.4 0.8 
50 49.97±.16 99.94 0.3 50.37±.53 100.74 1.1 
100 99.71±.61 99.71 0.6 99.69±.56 99.69 0.6 
Values = mean±SD * (n = 3), ** (n = 9) 
 
Table 2: Percent recovery obtained by standard addition technique 
Drug Conc. 
(50 μg/ml) 
Added Conc. μg/ml Conc. Found 
μg/ml 
Extraction recovery (%) CV (%) 
MTX 10 60.40±0.6 100.69±1.03 1.0 
25 75.27±0.5 100.35±0.68 0.7 
50 99.23±0.85 99.23±0.85 0.9 
DXM 10 60.37±0.73 100.61±1.22 1.2 
25 75.67±0.87 100.89±1.17 1.2 
50 99.2±1.05 99.2±1.05 1.1 
IND 10 59.96±0.89 99.93±1.48 1.5 
25 74.57±0.82 99.42±3.3 1.09 
50 100.7±1.2 100.7±1.2 1.1 
Values = mean±SD (n = 3) 
 
Table 3: System suitability parameters 
Drugs Methotrexate Dexamethasone Indomethacin 
Calibration range µg/ml 1-500 1-500 1-500 
Retention time (min.) 1.47  4.05  11.29  
HETP 111.46 53.845 33.354 
Tailing factor 1.54 1.32 1.35 
Theoretical plates 2071 2785 4497 
LOD (ng) 3.3  0.3  2.1  
LOQ (ng) 10.9 0.9  6.7  
Resolution factor                            11.163 14.834 
K’                            1.788 6.810 
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Table 4: Results of ruggedness study 
Samples Drugs Analyst 1 (μg/ml) Analyst 2 (μg/ml) % CV 
Sample I MTX 5.1±0.78 5.2±0.97 1.4 
DXM 5.06±0.59 5.2±0.86 1.9 
IND 5.2±1.02 5.29±.93 1.2 
Sample II MTX 10.14±1.26 9.9±1.12 1.7 
DXM 10.2±0.84 10.03±0.74 1.2 
IND 9.88±0.47 10.02±0.38 1.0 
Sample III MTX 24.97±0.27 25.65±0.41 1.9 
DXM 25.66±0.43 25.34±0.58 0.9 
IND 24.78±0.82 25.41±0.27 1.8 
Sample IV MTX 49.78±0.76 50.16±0.36 0.5 
DXM 50.78±0.69 51.25±0.34 0.7 
IND 49.76±1.04 50.46±0.57 1.0 
Sample V MTX 100.46±0.74 101.32±0.15 0.6 
DXM 100.96±0.25 99.82±0.34 0.8 
IND 99.54±0.39 99.04±0.24 0.4 
Values = mean±SD (n = 3) 
 
CONCLUSION 
A simple, sensitive, economic and reliable RP-HPLC method has been 
developed and validated for simultaneous estimation of 
methotrexate, dexamethasone and indomethacin using ibuprofen as 
an internal standard. The method is accurate, rapid, reproducible, 
specific and rugged for simultaneous determination of these drugs.  
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